INTRODUCTION
Adult-onset Still's disease (AOSD) is a systemic inflammatory disorder of unknown etiology. AOSD is characterized by repeated fever, joint pain, pharyngitis, hepatosplenomegaly, enlargement of lymph nodes, and a variable degree of pneumonitis. Multiple organ systems are frequently involved, and in rare cases, AOSD can manifest as severe pneumonitis [1] .
Although treatment usually commences with the application of non-steroidal anti-inflammatory drugs (NSAIDs), the addition of systemic glucocorticoids, disease-modifying antirheumatic drugs (DMARDs), and biologic agents such as tumor necrosis factor (TNF) inhibitors usually proves necessary [2] . However, certain cases of AOSD are refractory to these -The Korean Journal of Medicine: Vol. 87, No. 2, 2014 --246 -conventional agents. Anakinra, a recombinant human interleukin-1 (IL-1) receptor antagonist, demonstrates promising utility in such instances [2] . We report the first case, of AOSD with severe pneumonitis that failed to respond to steroids and cyclophosphamide but exhibited rapid clinical improvement following application of anakinra.
CASE REPORT
A 68-year-old Asian male presented to the emergency department complaining of episodes of fever that had occurred daily for more than 1 week and did not respond to NSAIDS. He reported that his fever occurred principally in the afternoon, persisted for 2-4 hours, and then subsided following a period of mild sweating. Associated symptoms included malaise, headache, sore throat, muscle ache, nausea, and vomiting. The patient had experienced an episode of AOSD 5 years previously that involved recurrent daily spiking fever, evanescent rash, and high ferritin levels. He was treated with a short course of steroids and has subsequently been afebrile.
During initial evaluation, the patient was thin and exhibited mild respiratory distress. His blood pressure was 140/80 mmHg, his pulse rate was 90 beats per minute, his respiratory rate was 20 breaths per minute, and his body temperature was 39℃. Emergency blood counts revealed leukocytosis with a left shift. Blood cultures were obtained, following which empiric antibiotics were initiated; the patient was then admitted for further evaluation. Transthoracic echocardiography results were unremarkable.
Thoracentesis revealed an exudate with 95% segmented neutrophils and no evidence of pulmonary tuberculosis or malignancy. Bronchoscopic alveolar lavage was negative for viral and pneumocystis pneumonia, and transbronchial lung biopsy revealed no diagnostic parenchymal abnormality. Serum tests for legionella and mycoplasma were also negative. Bone marrow biopsy revealed no evidence of hematologic malignancy, but reactive hyperplasia of granulocytic cells was detected.
Because follow-up tests for serum ferritin levels yielded values exceeding 10,000 ng/mL, with a maximum value of 70,000 ng/mL, a diagnosis of AOSD was entertained. Although evidence of arthralgias, lymphadenopathy, and hepatospleno- The patient's condition improved dramatically following only 1 day of anakinra treatment. Ferritin levels returned to normal, and pulmonary infiltrates cleared rapidly. Over the following days, the steroids were tapered off, while anakinra and cyclosporine were maintained for a total of 30 days.
Because it was unclear whether the patient's clinical improvement was attributable to cyclosporine or to anakinra, the latter was withheld to allow for observation of clinical changes.
Two days later, daily fever returned, the salmon-colored rash reappeared, and ferritin levels rose again (Fig. 2) . However, these symptoms disappeared immediately following reinstatement of anakinra. The patient was eventually discharged with anakinra and cyclosporine; treatment responsiveness was confirmed during outpatient follow-up following the tapering-off of cyclosporine.
DISCUSSION
The prevalence of pulmonary involvement in AOSD varies markedly across cases, ranging between 0 and 53% [1] . Pleurisy represents the most common pulmonary manifestation and can present alone or in addition to transient pulmonary infiltrates that frequently resolve without complication. Acute pulmonary abnormalities usually respond well to systemic steroids, but in certain cases, these abnormalities may progress to life-threateningly severe respiratory failure that requires mechanical ventilation [1] .
The similarities between clinical and laboratory presentations of AOSD and those of infectious diseases suggest a role for infectious agents in AOSD pathogenesis [3] . However, definitive evidence is currently lacking. Although genetic, environmental, and immunologic factors have also been implicated, conclusive evidence has not been forthcoming;
reports that specific HLA alleles are associated with AOSD still require corroboration [4] .
Although there are no definitive laboratory tests for AOSD, biomarkers can aid in differentiation of AOSD from infectious diseases. Serum ferritin levels ≥ 2,500 ng/mL appear to be highly specific to AOSD [5] . However, autoimmune disorders, inflammatory solid tumors, and hematologic malignancies can also express hyperferritinemia, albeit usually at lower levels [5] . Despite elevated inflammatory markers, culture results are negative, and antimicrobials have no effect on the clinical course. The pathognomonic rash observed in Still's Disease is fleeting, and it can be easily mistaken for a trivial skin disorder. Moreover, lung biopsy has not proven illuminating in the context of AOSD complicated by acute pneumonitis.
Hyaline membrane formation and type II pneumocyte hyperplasia indicate adult respiratory distress syndrome but do not contribute to the diagnosis of AOSD [1] .
AOSD is a diagnosis of exclusion, necessitating that a wide variety of similarly presenting disorders also be consid- Treatment of AOSD has long been empirical due to a lack of concrete data from randomized controlled clinical trials.
NSAIDs were once considered the first-line medication, but these have been largely replaced by corticosteroids due to low response rates, only 7-15%. Steroids are effective in approximately 75% of AOSD cases. Nevertheless, the adverse effects inherent to chronic steroid therapy, the relapses frequently seen in response to tapering, and resistance to their effects have all been of concern. Steroid-resistant AOSD is currently treated with DMARDs, with a response rate of nearly 60% [6] .
Evidence that cytokines play a central role in the patho- Although IFN-γ levels are also reportedly elevated in AOSD, this cytokine was not associated with disease activity [4] . Therefore, in contrast to rheumatoid arthritis, in which anti-TNF agents play an important therapeutic role, they have been used with only modest success in AOSD [4] .
The serum concentration of IL-1 level is markedly elevated in AOSD and is implicated in its pathogenesis. Recent studies suggest that dysregulation of IL-1 production resulting from an interplay of extrinsic and intrinsic factors is responsible for the maintenance of disease activity in AOSD [7] .
It has been suggested that anakinra may be an effective alternative therapy for AOSD patients. Anakinra is a recombinant version of a human IL-1 receptor antagonist that is administered subcutaneously at a dosage of 100 mg/day. Possible adverse reactions include headache, fever, nausea, arthralgia, nasopharyngitis, and increased risk of infection [2] , although none of these reactions was observed in our patient.
Patients treated with anakinra demonstrate rapid resolution of clinical and laboratory markers. Indeed, several authors have reported dramatic clinical improvements in response to its use [2, 4] . The effectiveness of anakinra and its corticosteroid sparing effect have been well documented in a case series of refractory AOSD reported by Oh et al. [8] In a study by Kontzias et al. canakinumab, a monoclonal antibody for IL-1 with a longer half-life, successfully controlled disease activity in anakinra-refractive cases [9] . Furthermore, because IL-6 shares an important pathogenetic role with IL-1, the IL-6 antagonist tocilizumab also has demonstrable effectiveness in anakinra-refractive AOSD [10] .
Withholding anakinra can result in clinical flare-ups and re-elevation of inflammatory markers. The relapse rate associated with anakinra therapy has not yet been determined, but long-lasting clinical remission is possible in response to tapering [3] . This suggests that IL-1 activity is responsible for the main inflammatory process observable in certain AOSD patients.
To the best of our knowledge, this is the first reported case of successful treatment of AOSD with severe pneumonitis using anakinra. Our study demonstrates that anakinra is 
